Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Defronzo

Showing results (11-20 of 313) with videos related to

Pageof 32
Sort By:
Cardiovascular Diabetology|August 7, 2009
Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body typeYoshinori Miyazaki, Ralph A DeFronzo
Diabetes Care|April 29, 2011
Type 2 diabetes can be prevented with early pharmacological interventionRalph A DeFronzo, Muhammad Abdul-Ghani
Diabetes & Vascular Disease Research|May 1, 2007
The insulin resistance syndrome: physiological considerationsSangeeta R Kashyap, Ralph A Defronzo
Diabetes|July 15, 2025
Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A ReviewRalph A DeFronzo, Richard J Auchus
Diabetes, Obesity & Metabolism|March 18, 2022
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetesRalph A DeFronzo, George L Bakris
The American Journal of Cardiology|August 2, 2011
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucoseRalph A DeFronzo, Muhammad Abdul-Ghani
Endocrine Reviews|May 4, 2019
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing AgentsAntonino Di Pino, Ralph A DeFronzo
Diabetes Care|July 23, 2017
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes AlgorithmMuhammad Abdul-Ghani, Ralph A DeFronzo
Expert Opinion on Pharmacotherapy|August 26, 2021
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?Muhammad Abdul-Ghani, Ralph A DeFronzo
The Journal of Clinical Endocrinology and Metabolism|March 1, 2007
Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretionMuhammad Abdul-Ghani, Ralph A DeFronzo
Pageof 32

Showing results (11-20 of 313) with videos related to

Sort By:
Pageof 32
Cardiovascular Diabetology|August 7, 2009
Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body typeYoshinori Miyazaki, Ralph A DeFronzo
Diabetes Care|April 29, 2011
Type 2 diabetes can be prevented with early pharmacological interventionRalph A DeFronzo, Muhammad Abdul-Ghani
Diabetes & Vascular Disease Research|May 1, 2007
The insulin resistance syndrome: physiological considerationsSangeeta R Kashyap, Ralph A Defronzo
Diabetes|July 15, 2025
Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A ReviewRalph A DeFronzo, Richard J Auchus
Diabetes, Obesity & Metabolism|March 18, 2022
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetesRalph A DeFronzo, George L Bakris
The American Journal of Cardiology|August 2, 2011
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucoseRalph A DeFronzo, Muhammad Abdul-Ghani
Endocrine Reviews|May 4, 2019
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing AgentsAntonino Di Pino, Ralph A DeFronzo
Diabetes Care|July 23, 2017
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes AlgorithmMuhammad Abdul-Ghani, Ralph A DeFronzo
Expert Opinion on Pharmacotherapy|August 26, 2021
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?Muhammad Abdul-Ghani, Ralph A DeFronzo
The Journal of Clinical Endocrinology and Metabolism|March 1, 2007
Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretionMuhammad Abdul-Ghani, Ralph A DeFronzo
Pageof 32